BridgeMD
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)
EU CTIS ID: 2022-501478-21-00
What this study is testing
To describe long-term safety of lebrikizumab in pediatric participants with moderate-to-severe AD
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have received treatment from study J2T-MC-KGBI
- Have completed study treatment from study J2T-MC-KGBI
You likely can't join if
- Have developed a serious adverse event from participation in study J2T-MC-KGBI
- Have developed an adverse event from participation in study J2T-MC-KGBI
The study team makes the final eligibility decision.
Where it's taking place
- Brazil
- United States
- Mexico
- Japan
- Argentina
- Taiwan
- Australia
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brazil; United States; Mexico; Japan; Argentina; Taiwan and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.